The 22nd century Group Inc. (XXII) is a biotechnology and tobacco innovation company known for its VLN® (very low nicotine) cigarettes. The company aims to reduce smoking addiction and provide health-friendly alternatives to people.
Latest updates 22nd century Group Inc
Q2 In 2025, the company’s turnover was $ 4.1 million, under the 1,2 quarter ($ 6.0 million).
The net loss was registered at about $ 3.3 million, but the amount of cigarettes increased by 86%.
The company has expanded its VLN® product in 44 states.
In collaboration with Pinakal, the products will now be available in around 1000 stores.
The company will present a new prototype of 100 mm VLN® sigarette to the FDA in Q4 2025.
Warehouse
The XXII share is currently around $ 1.97, and it’s almost the lowest level of the 52 weeks.
This is a risky, but potentially lucrative share for investors, as the FDA will soon make a final decision on the nicotine limit of 0.7 mg/g.
The expectations of the future
If the new FDA rule is used, the 22th century group can be distributed because their VLN® products already follow this standard.
✅ Conclusions: The company is currently in the red, but regulatory support and new partnerships can increase in the long run. The XXII share falls into the high-risk category.
Also Read: HAL Share Price & LCA Mark 1A Fighter Jets: Latest Updates on Hindustan Aeronautics
About The Author
